The United States has banned imports from three Chinese genomics companies over allegations involving forced labour and the collection of genetic material linked to the surveillance of persecuted ethnic minorities in China’s Xinjiang region.
The decision affects BGI Genomics, MGI Tech and Shenzhen BGI Technology, also known as BGI Group.
According to a report published by Punch Newspapers on October 29, the United States Department of Homeland Security added the companies to the Uyghur Forced Labor Prevention Act Entity List.
The development represents another escalation in the ongoing economic and technological tensions between Washington and Beijing.
The American government said the companies were allegedly involved in activities connected to the recruitment, transportation or use of forced labour involving Uyghurs, Kazakhs, Kyrgyz and other persecuted groups in Xinjiang.
It also raised concerns about the collection of genetic material that could be used to monitor members of these communities.
Reason behind the American decision
The Uyghur Forced Labor Prevention Act is part of the United States’ efforts to prevent products associated with forced labour in China’s Xinjiang region from entering the American market.
The legislation establishes restrictions on imports connected to certain activities in the region unless importers can demonstrate that the products do not involve forced labour.
The Department of Homeland Security said the three companies were linked to activities that justified their inclusion on the enforcement list.
The decision also reflects wider American concerns about the use of biotechnology and genetic information.
Genomics companies work with genetic material and technologies used in research, medical testing and other scientific applications.
While such technologies have important medical and scientific benefits, concerns have emerged internationally about how genetic information may be collected, stored and used.
The United States government argued that the companies’ alleged activities raised serious human rights concerns.
China rejects the allegations
China strongly rejected the American decision.
According to the Punch report, a spokesperson for China’s Commerce Ministry described the action as lacking a factual basis and accused Washington of using human rights concerns as an excuse for protectionism.
Beijing also warned that it would take necessary measures to protect its interests.
The affected companies similarly denied the allegations.
BGI and MGI said they opposed all forms of forced labour.
The disagreement illustrates the competing positions of both governments regarding human rights, international trade and technological competition.
While the United States maintains that the restrictions are necessary to address human rights concerns, China argues that Washington is using such policies to limit the activities of Chinese companies.
Wider implications for biotechnology and trade
The decision could have implications for international biotechnology companies, manufacturers and businesses operating across global supply chains.
Companies that depend on Chinese suppliers may need to review their sourcing arrangements and ensure compliance with American import regulations.
The development could also increase scrutiny of international biotechnology partnerships and the handling of genetic information.
The United States has already expressed concerns about Chinese involvement in strategic technology sectors, including artificial intelligence, semiconductors and biotechnology.
The latest import restrictions therefore form part of a broader pattern of economic and technological competition between both countries.
For international businesses, regulatory uncertainty could create additional compliance costs and affect decisions about where to manufacture, source materials and establish partnerships.
The controversy also highlights the importance of transparency and accountability in the biotechnology industry.
As genetic technologies become increasingly important in healthcare and scientific research, governments and companies face growing pressure to protect individual rights and ensure that sensitive information is handled responsibly.
The American restrictions are expected to remain an important issue in discussions about trade relations and technological competition between Washington and Beijing.
